Genomcore reinforces its national leadership with the opening of its new strategic headquarters in Madrid

Genomcore reinforces its national leadership with the opening of its new strategic headquarters in Madrid

Genomcore, the leading technology company in biomedical data management for driving precision medicine, marks a milestone in its roadmap with the inauguration of its new headquarters in the Spanish capital. This strategic move responds to the solid expansion and increased activity in key national projects, reaffirming the company's commitment to the effective implementation of precision medicine in the real world, beyond the academic sphere.

This opening in Madrid strengthens Genomcore's institutional presence and operational capacity in the nerve centre of the Spanish healthcare ecosystem. The company is already at the forefront of major initiatives, demonstrating its expertise and national reach.

Genomcore leads key projects such as SIGenES, the national genomic information exchange network for the National Health System, and DIPCAN, the most ambitious publicly funded artificial intelligence project in oncology in Spain. Furthermore, Genomcore BIMS serves as the technological foundation for strategic programs such as OMIQ-HES in Catalonia, Osagen in the Basque Country, and the Medigenomics initiative in the Community of Madrid, among others. These projects, combined, confirm Genomcore’s technology and expertise for charting the future course of personalized medicine.

The new offices are strategically located on the Paseo de la Castellana, in the heart of the Chamartín district. Genomcore thus integrates into the Madrid Health Hub, a key space that concentrates health innovation and talent.

"This new office in Madrid is not just a geographical milestone, but a springboard for scaling our mission: bringing precision medicine to every corner of the country. Being here allows us to be closer to our partners and key strategic decision-making centres," states Dr. Óscar Flores, CEO of Genomcore.

For his part, Miquel À. Bru, Cofounder & CBDO, underlines the importance of this location: "The capital was a fundamental piece for our consolidation. From the heart of Spain, we will drive public-private collaboration in health and demonstrate that Spanish biomedical technology, with its rigour and vision, is ready to lead Europe. It is the natural evolution to continue consolidating the high-impact projects we already have underway."

The consolidation in Madrid is essential to the company's strategy for continuing to lead the harmonization and secure exploitation of multimodal health data. Genomcore is positioned as the partner that facilitates responsible innovation and regulatory compliance for health systems, hospitals, corporations, and startups in the digital health sector, ensuring the maximum protection of data.